ep move
ow pt
upheav pharmaci benefit pbm landscap via
competitor government-l drug price reform
posit underappreci share gain
acceler profit growth follow unh/medco
pbm transit playbook consensu ep
upgrad ow
evolut pbm market model greatli advantag integr
manag care /pbm solut view bring
pbm in-hous dust settl extrem activ
month space regulatori chang view integr
mco/pbm win model post-drug-rebate/increas transpar
world exhibit shift occur next year see step-
function opportun outsourc pbm express
script benefit exit contract exhibit ad
playbook effect transit pbm acceler growth written
execut leadership view
direct analog drawn integr pbm
medco pbm optumrx market
tilt toward integr medical/pbm solut exhibit base
analysi file transcript optumrx significantli outgrew
reason expect exhibit thu model increment
billion pbm-driven pre-tax profit first full year post-
transit compris manag estim exit
contract increment driven increas pbm penetr
health plan live exhibit addit think
underestim anthem ceo gail boudreaux ceo
healthcar facil manag unit state
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
unitedhealthcar health insur busi
exact time-frame unitedhealth/optumrx success integr
pbm medco thu see lower-than-typ execut risk
see pbm growth posit feedback loop core growth includ
medicar advantag medicaid well enhanc capit deploy
tighter integr pharmaci medic benefit enhanc
margin opportun compet new busi medicar
medicaid addit model heighten capit deploy could
consist tuck-in akin recent deal share repurchas pbm
acceler free cash gener access unregul capit start
total model high-teen averag earn growth
equat ep versu previou high-single-/low-double-digit
target growth manag consensu ep
despit acceler growth trade rel discount
current ntm price-to-earnings share trade averag price-to-earnings discount
in-lin discount premium
see exhibit forward earn growth averag high teen
next year model versu past year see
compel valu rel coverag broader healthcar
price target prior base price-to-earnings multipl
appli base case ep discount back
oper driver price target rais in-sourc pbm
capit deploy see exhibit base case multipl assum
expans current ntm price-to-earnings price target full first-year
benefit post-pbm transit roll-forward prior price target
bull case valuat assum pbm profit growth acceler drive
outsiz enrol growth result multipl expans bear case
valuat driven inabl execut pbm transit
could wrong execut pbm on-board
run smoothli result membership dissatisfact enrol declin
profit loss govern growth fail materi gain scale slow overal
growth rate price competit particularli govern busi put
pressur margin
calcul price target appli price-to-earnings multipl in-lin
averag ntm multipl base case ep
discount back
bull case ep discount back year
bull case ep discount back year
pbm transit exce goal result increment enrol gain
membership accumul continu base busi pbm effici
drive greater pbm profit penetr base case
well health plan enrol growth bull case multipl halv
histor discount
base case ep discount back year
base case ep discount back year
penetr upsid transit pbm live esrx run smooth
ad increment pre-tax earn better
esrx price remain better penetr within health
plan book medicare/medicaid capit deploy acceler non-pbm
growth base case price-to-earnings multipl line ntm price-to-earnings
bear case ep
bear case ep
failur execut pbm transit result lost profit opportun
enrol bear case multipl slight discount
consist grown
membership past sever year
across self-fund fulli insur
transit in-hous pharmaci
benefit busi pbm express script
result signific profit opportun
inclus save better term
current contract well greater
medicar advantag medicaid
greater pbm effici well
come fail ci merger
flexibl deploy capit share
purchas
bp add ep
advantag bp add
updat pbm transit
risk achiev price
pbm transit delay poor execut
result lower profit lost member
capit deploy delay
price pressur govern
commerci busi result margin
upgrad overweight equal-weight
upgrad ew ow increas price target
see clear path inflect earn growth trajectori mid-
high singl digit today low doubl digit new manag driven
move pbm esrx in-hous increment penetr pbm
exist health plan busi continu success govern
program medicar advantag medicaid benefit effici pbm
drive enhanc capit deploy current trade discount
closest peer substanti wider averag last year
growth like acceler near/midterm valuat discount clear
nois see catalyst share remaind head guidanc
januari
exhibit earn bridg
drug price reform take us healthi skeptic
pbm prospect bull
announc would bring pbm in-hous octob
somewhat unconvinc potenti market impact recal last octob
outsourc pharmaci benefit manag function express script
better part current decad announc would bring pbm function
back in-hous start member would transit new pbm platform
ingeniorx member transit provid back-
offic function would transit next year onto pure anthem
platform modul see solo pbm stori question save
manag estim break tie express script includ
drug cost save million would drop earn line
clear profit averag express script client
exhibit uncertainti driven valu unders pbm exhibit
would like better term scale whether
would drive addit growth beyond initi cost save
exhibit anthem rx profit esrx rel
manag pharmaci benefit activ acceler consider past
month start announc bring pbm in-hous
script octob last year see solo pbm stori manag care pharmaci
benefit compani quickli come togeth announc acquisit
aetna see welcom vertic integr decemb potenti form
retail-driven vertic integr provid medic pharmaci servic akin
cvs/aet announc acquisit express script
would add pbm capabl approv regul sharehold alreadi
approv propos deal left medicaid-focus mco made
pbm move includ wellcar acquisit meridian potenti switch
meridianrx pbm platform see acquir medicaid medicar
manag pharmaci benefit invest rxadvanc see
major announc structur chang pharmaci benefit
market rang announc amazon/jp morgan/berkshir
hathaway ventur aim reduc healthcar cost see amazon berkshir jpmorgan
disrupt amazon acquisit pillpack see
pillpack acquist chang healthcar industri aetna
respect announc combin would convert million fulli insur
live point sale po pharmaceut rebat see point sale rebat come
soon pharmaci near seen exhibit clear pbm activ
acceler question remain dust settl
exhibit acceler evolut pbm market past month
faster pace mco/pbm activ could chalk overal healthcar
vertic integration/consolid quest growth see three potenti
next decad pharmaceut spend growth like outpac hospit
spend growth data releas earlier year
expenditur nhe project nhe
demonstr shift per capita spend hospit care grew
annual prescript drug spend grew
annual period like aid gener
wave next year howev project hospit care
acceler bp annual growth prescript drug spend acceler
bp annual growth specialti pharmaceut continu growth
innov continu person medicin exhibit manag
care perspect medic cost trend remain fairli stabl driven new
plan design high deduct plan integr care pharmaceut
trend manag could greater opportun
outcomes-bas price yet signific grow opportun
address cost trend requir tighter pharmaceut integr outcom
base arrang pharmaceut manufactur take risk
outcom particularli expens specialti therapi prepar statement
hous judiciari committe earlier month see cvs/aet goe
washington aetna gener counsel thoma sabatino jr said date
enter around agreement manufactur pay base
therapeut valu deliv incentiv appropri medic manag
servic make drug success see full testimoni
manag care perspect expect type agreement acceler
pace innov see integr pharmaceut servic medic
care data key subtl shift brand pharmaceut price toward
valu current rebat driven structur
think on-going debat drug price hh print drug
price reform underappreci boon integr manag care
pbm player print drug price reform see announc
goal reduc cost drug individu unit
state increas transpar pharmaceut suppli chain although
met skeptic individu program come light
elimin rebat safe harbor medicar part potenti impact
across space pick steam role rebat particular
debat last sever month point profit
pbm middlemen ad limit valu end user medic given
forc plu pend signific shift
relationship manag care pbm mco-affili pbm top
share us prescript market versu year ago
exhibit nhe per capita spend compound-annual-growth-rate hospit prescript
exhibit estim market share us adj rx mco-affili
mco alreadi begun embrac post-reb world wrote march
start transit point sale rebat system
full risk member million live see much ado pharmaci decod
posit futur drug price system major rebat
given individu purchas drug increas overal system transpar
versu typic rebat scenario rebat paid singl pool bake
premium reduc overal cost member aetna announc shortli
would similarli go point sale rebat system million full risk
member see march press releas
announc point sale rebat system note
confer call juli ceo gail boudreaux point toward pbm focu net cost
let begin first foremost focus reduc net
overal drug price think realli goal industri certainli goal
launch ingeniorx term valu proposit laid
billion growth save fall bottom line confid
feel prudent number see chang
support anyth build new gener next-gener pbm
realli get lowest net cost think realli import
build base rebat model build base net lowest
cost valu model support want ensur
everyth get implement realli result lower cost consum
realli focu ingeniorx earn call
think plan sponsor employ govern etc littl incent
separ medic pharmaci benefit go forward creat signific upsid
opportun bring pbm in-hous prior drug print
releas move point sale rebat aetna begun
see increas interest plan sponsor combin benefit april
alphawis survey benefit manag see pbm survey po rebat integr
analyst ricki goldwass note respond prefer integr pbm
model two year ago exhibit half would consid bundl
pharmaci medic exhibit increas willing combin medic
pharmaci benefit combin limit select stand-alon pbm post
pend cvs/aet merger ci/esrx merger prescript volum
us flow non-integr mco/pbm
exhibit respond prefer integr pbm model
exhibit half survey popul would consid bundl
pharmaci medic benefit
signific pbm share gain opportun within healthplan book
benchmark estim current pbm via
script roughli adj rx/member million adjust rx compar
million cover live compar unitedhealth/optum rx
adj rx/life billion adj rx unitedhealth million live
reason differ includ optumrx acquisit catmaran
well success win pbm busi outsid core
said see room increas pbm penetr without win stand-
alon pbm busi drive profit growth
integr medco busi serv guid
opportun recal prior outsourc larg portion
pbm busi medco health solut later acquir
script see pbm holi grail announc would begin
transit million live million adjust rx onto optumrx
platform cours member would
optumrx pbm dug file transcript
time period express script focus
acquir catamaran increas optumrx scale note
observ point signific upsid bring pbm in-hous
optumrx total adjust script grown integr
medco live actual grew exhibit
period time total member enrol grew adj/rx
per member basi grew adj rx/member
pbm profit margin expand significantli transit period pbm
margin expand bp invest year on-board pbm
suspect increas scale/purchas power
also view like effici oper versu outsourc medco
set-up optumrx win non-unitedhealthcar live futur note
post acquisit catamaran optumrx grown largest
pbm follow number adjust script despit percept
affili would prevent optumrx grow
particularli smaller health plan custom continu grow share
expect exhibit recent mention competit health plan
win earn call see
exhibit optumrx report adj rx versu expect in-
exhibit report pbm margin
esrx
compani data note optumrx report segment oper margin pre-interseg
elimin esrx report ebtida margin
ceo happen journey pbm member transit
new platform complex potenti result custom
dissatisfact new id card procedur call center backend softwar offer
new touchpoint could go awri therefor think
overemphas enough import leadership
experi fortun ceo gail boudreaux took mantl
novemb ceo unitedhealthcar health insur busi
group exact time-frame /optum
integr pbm medco thu see lower-than-typ execut risk given
success transit well understood blueprint expand
base opportun increas pbm scale/penetr model
billion increment pre-tax profit growth pbm alon
equat increment ep growth core growth next year
compar million profit impact estim manag
esrx transit alon base case assum pbm penetr increas
adj rx/enrol health plan life still significantli lower unitedhealth
oper margin rang also optumrx exhibit
exhibit provid sensit base prescript penetr oper
exhibit pbm in-sourc ebitda sensit script penetr increment pbm
note figur hundr million ebitda compani data morgan stanley research
exhibit pbm in-sourc ep sensit script penetr increment pbm
contribut growth
medicaid medicar advantage/part like continu sourc
growth organ via rel two closest diversifi
comp slightli less penetr govern busi
slightli aetna exhibit follow two tuck-in
acquisit medicar advantag expect continu
invest growth govern busi improv pbm serv
lynchpin make price margin competit peer
exhibit govern mix diversifi mco
write improv medicaid environ recent
state medicaid what chang sinc march primer work requir
interest increas medicaid expans also note strength
pipelin least contract award next month exhibit
repeatedli cite pipelin opportun next year
activ look cbo project medicaid add peopl
wisconsin milwauke dane counti
texa chip
exhibit cbo estim medicaid coverag
medicaid repres medic membership member
book busi larg portion total compani grown
stand exhibit
exhibit medicaid total medic membership
although kansa lost small contract minim ep contribut
recent kansa releas medicaid contract award exclud one
incumb state medicaid market kansa live
serv total medicaid membership total medic
membership estim margin repres revenu
ep contract end compani
current protest decis
medicar advantag one fastest grow area manag care recal
current repres medicar beneficiari
peopl exhibit cbo estim penetr reach
exhibit tailwind includ age popul online-pric
comparison savvi popul appeal two-fold everi compani grow
fight market share much profit
manag care compani given narrow network valu base care
exhibit percentag overal medicar
footprint market share grow histor
largest concentr popul typic own low- mid-
single-digit market share year exhibit decemb januari
compani close acquisit space note capit
deploy option section expand footprint florida south
carolina slightli increas overal market share medicar
advantag advantag note rank state term attract south carolina
score top quartil florida second quartil notabl
high level medicar popul room penetr green
opportun part pdp market could aris pbm shift in-hous
current market domin member
compar member inclus combin ma-pdp member
exhibit effici pbm next sever year expect
competit organ part busi well potenti
stay fray larg follow termin deal acquir cigna
compani refocus effort tuck-in deal like
close execut strategi other initi larger-scal
acquir compani focus medicar advantag
deal term disclos expect slightli accret
septemb compani announc intent acquir healthsun
close decemb compani oper florida offer
star rate health plan cover member southern
octob compani announc intent acquir america choic
close earli health plan oper florida south
carolina member like healthsun compani offer product
recent announc acquisit aspir health may
compani announc acquisit exclud deal term expect close
deal expect slightli accret start aspir health
palli care provid exclud hospic servic use algorithm
integr care team physician nurs social worker work
need coordin manag care compani footprint state
health plan custom
look acquisit go back even
caremor wrap around put capit intens
high cost area actual think strong return make
signific differ cost care overal actual improv qualiti
would like point acquisit think great exampl
capabl help us support medicar advantag popul lead
capabl think leverag think interest
lie quit opportunist look capabl help support
drive cost care qualiti marketplac earn call
said capit deploy
capit prioriti reiter new ceo right gate new ceo gail
boudreaux commit continu capit prioriti previous laid
invest busi first use follow
balanc share repurchas dividend
 comment point bolt-on deal sinc begin tenur ms
boudreaux signal strategi smaller deal rather
large-scal seen other sector
believ coordin thought long-term strategi drive plan
disciplin leverag pipelin help build anthem
long-term evalu strateg posit enhanc
current asset base capit opportun tomorrow earn
first two acquisit leadership close ms boudreaux point
shine exampl expect deal along repres
futur forese futur deal highli
complementari high regulatori hurdl
quarter complet acquisit america choic
ad medicar advantag live central florida acquisit along
acquisit healthsun late align strategi grow
busi deep integr market serv earn call
broadli think one uniqu thing think
deep market presenc signific organ growth opportun
insid busi go leverag take advantag
also opportun scale local scale partnership
effect leverag capit effici way
abil deploy capit
leverag consist mco histor current oper
debt total capit seen larg transform deal exhibit
ratio flex rang histor compani oper
rang movement higher announc three
deal last month healthsun america choic
move leverag leav room flex balanc sheet
exhibit diversifi leverag debt total capit
look fairli attract free cash gener perspect free cash
flow yield converg exhibit although yield increas
sole due pend deal termin per share basi anthem
consist gener higher level free cash exhibit
view closest comp
rare discuss compani pay dividend discuss capit
deploy dividend usual last item mention take rein ms
boudreaux commit capit prioriti share repurchas
dividend behind intern invest
priorit make necessari invest busi first
evalu opportun exist market final deploy capit
sharehold balanc approach share buyback dividend gail
rel basi dividend pay-out ratio trail exhibit
gap widen last year appear verg narrow
would expect compani step pay-out ratio lieu signific
lack opportun buy back share
model extend includ pbm transit
model ep vs consensu includ
moratorium health insur fee hif well normal growth
core book includ invest transit pbm live model
share repurchas contribut ep in-line histor
ep estim in-line consensu includ
transit half contribut pbm live esrx stagger
cours year live transit net estim
pbm add increment ep normal growth core
health plan model share repurchas contribut ep
abil deploy capit acceler
model ep vs consensu although note
current estim includ full contribut million
bring esrx pbm live in-hous well increment
growth pbm penetr combin model pbm contribut
equat increment ep pre-pbm transit
despit acceler growth opportun current trade discount
rel current trade ntm price-to-earnings price-to-earnings
price-to-earnings exhibit histor last year
trade discount compar current ntm basi
trade discount exclud pbm
earn exhibit view pbm higher earn growth profil
start make look closer mean narrow gap warrant
exhibit ntm price-to-earnings rel
exhibit vs peer price-to-earnings basi
introduc price target deriv price target appli
multipl earn discount back one year
multipl impli multipl expans current ntm price-to-earnings despit
acceler growth profil price target repres premium current
bull bear case hing pbm execut bull case valuat consist
price-to-earnings multipl halv histor discount appli bull
case ep discount assum pbm profit approach
billion via greater penetr core health plan book well growth
medicar medicaid bear case valuat consist price-to-earnings multipl
discount averag appli bear case ep bear
case assum pbm execut delay save esrx fail reach
million margin/enrol pressur medicar advantag medicaid
price free cash flow metric reveal also under-valued compar
free cash flow per share grow annual faster pace
time price reflect growth result free cash flow yield
lower gap two compani grow
exhibit outlin compani move
growth trajectori closer gap narrow widen
exhibit price free per share
follow announc intern pbm stock reach new level
stock began ralli follow ingeniorx announc earn result
exhibit sinc time stock found new technic level support around
recent high approach largest downward move year
relat amzn/jpm/berkshir jv announc end januari
detail amazon berkshir jpmorgan disrupt note
howev ytd share under-perform non-deal mco exhibit
exhibit share perform news event
gener administr expens net dep
sg expens net depreci
amort goodwill/intang
incom tax
incom non-recurring item
non- adjust
benefit expens ratio premium
sg net revenu
sg revenu way wlp guides/report
tax rate hif
cash equival
total invest available-for-sal fair valu
premium self-fund receiv
long-term invest avail sale fair valu
restrict cash invest
liabil sharehold equiti
account payabl accru expens
current portion long-term debt
reserv futur polici benefit non-current
total liabil sharehold equiti
consolid statement
net realiz capit loss non-recur item
amort net accret
chang oper asset liabil
net cash provid oper
net sale purchas invest
net purchas properti equip
acquisit net cash
net cash provid invest activ
net proce commerci paper borrow
proce short-term borrow
proce long-term borrow
repay short-term borrow
repay long-term borrow
chang secur lend payabl
chang bank overdraft
issuanc common stock
repurchas retir common stock
proce exercis option esop
excess tax benefit share base comp
net cash provid financ activ
net increas cash equival
adj net op profit inc net inv incom excl int exp
chang statutori risk-bas capit
increas /decreas work capit
unlev after-tax free parent
pv oper free parent
less provis tax
prem per
weight averag capit wacc
discount valu termin valu
equiti
debt
debt after-tax
weight averag equiti
time valuat
year termin valu
act financi advisor corpor connect
definit agreement wherebi acquir express script hold
compani express script announc march propos transact
subject approv express script sharehold applic
regulatori approv customari close condit report
inform provid herein intend provid vote advic ii serv
endors propos transact iii result procur withhold
revoc proxi action secur holder agre
pay fee financi servic includ transact fee
conting upon consumm transact pleas refer note end
report
